FY2030 Earnings Forecast for TARA Issued By HC Wainwright

Protara Therapeutics, Inc. (NASDAQ:TARA) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Protara Therapeutics in a research note issued to investors on Wednesday, March 11th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.09) per share for the year. HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Several other brokerages have also commented on TARA. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. JPMorgan Chase & Co. assumed coverage on shares of Protara Therapeutics in a report on Wednesday, March 4th. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, Piper Sandler began coverage on Protara Therapeutics in a research report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Protara Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Protara Therapeutics Stock Down 1.9%

Shares of TARA stock opened at $5.60 on Thursday. The firm has a market capitalization of $289.13 million, a price-to-earnings ratio of -4.24 and a beta of 1.40. The stock has a fifty day moving average of $6.10 and a 200 day moving average of $5.35. Protara Therapeutics has a 52 week low of $2.77 and a 52 week high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TARA. Janus Henderson Group PLC boosted its stake in Protara Therapeutics by 21.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock worth $27,379,000 after acquiring an additional 910,285 shares in the last quarter. Velan Capital Investment Management LP lifted its holdings in shares of Protara Therapeutics by 32.5% during the fourth quarter. Velan Capital Investment Management LP now owns 2,834,652 shares of the company’s stock valued at $15,109,000 after purchasing an additional 695,652 shares during the last quarter. Integral Health Asset Management LLC boosted its position in shares of Protara Therapeutics by 60.7% in the 4th quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock worth $11,992,000 after purchasing an additional 850,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Protara Therapeutics by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock worth $8,283,000 after buying an additional 102,176 shares during the last quarter. Finally, Acorn Capital Advisors LLC grew its stake in shares of Protara Therapeutics by 36.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock worth $5,309,000 after buying an additional 472,315 shares during the last quarter. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.